Wire · opportunities
Could FDA-evaluated tissue chips succeed where animal testing falls short?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Researchers at the University of Rochester have achieved a key FDA milestone by having their tissue chip technology accepted into the FDA's ISTAND pilot program. This platform uses human cell-based chips to predict immune-related toxicities of cancer immunotherapies more accurately than animal testing, aiming to improve and potentially replace preclinical drug safety studies.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure, and 2 sources have reported it between 11 Aug 2026 and 24 Aug 2026.
◆ ◆ The Wire takeaway
Your drug discovery efforts will soon face new standards where human cell tissue chips could shorten the path to FDA approval by offering better prediction of immune toxicities than animal tests. This opens a new route for biotech founders to cooperate directly with regulators and pharma for safer immunotherapy trials.
◆ Coverage
2 sources · first reported 11 Aug 2026 · latest 24 Aug 2026
◆ Related on Wire
◆ Topics